The history of the erectile dysfunction drug presents a intricate picture for investors. While the initial release generated substantial gains, the lapse of its exclusive rights opened the floodgates to off-brand competitors, dramatically diminishing sales. This presents a specific risk for drug manufacturers relying on comparable blockbuster offer

The story of Viagra, and its developer copyright, presents a complex case study for investors. Originally a blockbuster drug, producing billions in sales , its exclusivity period created a flood of generic competition , significantly eroding its market share . While some firms may seek to capitalize on similar conditions , the present landscape dem